Ítem
Acceso Abierto

Evidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológico

Mostrar el registro sencillo de la publicación
dc.contributor.advisorHernandez-Castro, John-Jairo
dc.creatorBarbosa Villada, Maria
dc.creatorBorda Restrepo, Diana
dc.creator.degreeEspecialista en Toxicología Clínica
dc.date.accessioned2016-08-30T19:33:53Z
dc.date.available2016-08-30T19:33:53Z
dc.date.created2016-08-04
dc.date.issued2016
dc.descriptionContexto: La eficacia de los cannabinoides en el dolor neuropático es desconocida. El control del dolor es determinante en los pacientes ya que genera un impacto negativo en la calidad de vida de los pacientes. Objetivo: El presente trabajo pretende demostrar la evidencia sobre la eficacia de los medicamentos cannabinoides en el control del dolor neuropático oncológico, mediante la evaluación de la literatura disponible. Metodología: Se realizó una revisión sistemática de literatura incluyendo estudios experimentales, observacionales y revisiones sistemáticas en un periodo de 15 años. Se incluyeron todos los estudios desde el años 2000 con evidencia IB según la escala de evidencia de Oxford. Resultados: Cuatro estudios cumplieron criterios para su inclusión, sin embargo la evidencia es baja y no permite recomendar o descartar los cannabinoides como terapia coadyuvante en control del dolor neuropático oncológico. La combinación de THC/CDB (Sativex®) parece ser un medicamento seguro pues no se reportaron muertes asociadas a su uso, sin embargo la presentación de eventos adversos a nivel gastrointestinal y neurológico podría aumentar el riesgo de interacciones medicamentosas y tener un impacto negativo en la calidad de vida de los pacientes oncológicos. Conclusiones: No hay suficiente literatura y la evidencia no es suficiente para recomendar o descartar el uso de los cannabinoides en dolor neuropático oncológico. Futuros estudios deben realizarse para analizar el beneficio de estos medicamentos. Aunque ética y socialmente hay resistencia para el uso de los cannabinoides, actualmente hay una gran discusión política en el mundo y en Colombia para su aceptación como terapia en el control del dolor.spa
dc.description.abstractBackground: The efficacy of cannabinoids in neuropathic pain is still unknown. Pain management is critical for patients because it creates a negative impact on the quality of life of patients. Objective: This study aims to demonstrate the evidence towards the effectiveness of cannabinoid drugs in controlling oncological neuropathic pain, by evaluating the available literature. Methodology: A systematic review of literature was conducted including experimental, observational studies and systematic reviews over a period of 15 years All studies since 2000 with Oxford evidence scale as IB were included. Results: Four studies met criteria for its inclusion, but the evidence is low and does not allow to recommend or discard cannabinoids as adjunctive therapy in cancer control neuropathic pain. The combination of THC / CBD (Sativex) appears to be safe for its use, and is not associated with deaths reported, however the presentation of adverse gastrointestinal and neurological level events could increase the risk of drug interactions and have a negative impact on the quality of life of cancer patients. Conclusions: There is not enough literature and evidence is not sufficient to recommend or discard the use of cannabinoids in neuropathic cancer pain. Future studies should be conducted to analyze the benefit of these drugs. Although ethically and socially there is resistance to the use of cannabinoids, there is currently a great political discussion in the world and in Colombia for acceptance as therapy in pain control.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_12311
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/12311
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Medicinaspa
dc.publisher.programToxicología Clínicaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto completo)spa
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombiaspa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.source.bibliographicCitationSerpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012
dc.source.bibliographicCitationPoulin PA, Romanow HC, Rahbari N, Small R, Smyth CE, Hatchard T, et al. The relationship between mindfulness, pain intensity, pain catastrophizing, depression, and quality of life among cancer survivors living with chronic neuropathic pain. Support Care Cancer [Internet]. 2016 May 18 [cited 2016 Jun 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27193116
dc.source.bibliographicCitationRahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics [Internet]. 2009 Oct [cited 2016 Jun 3];6(4):713–37. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2755639&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationRahn EJ, Makriyannis a, Hohmann a G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol [Internet]. 2007;152(5):765–77. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2190028&tool=pmcentrez&rendertype=abstrac
dc.source.bibliographicCitationBushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol [Internet]. 2010 Feb [cited 2016 Jun 3];10(1):80–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2818338&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationUrch CE, Dickenson a H. Neuropathic pain in cancer. Eur J Cancer [Internet]. 2008;44:1091–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18492553
dc.source.bibliographicCitationRayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, et al. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med [Internet]. 2013;27:714–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23175513
dc.source.bibliographicCitationOMS. Envejecimiento activo: un marco político. Rev Española Geriatría y Gerontol. 2002;37(2):74–105
dc.source.bibliographicCitationPatel NB. Guide to Pain Management in Low-Resource Settings.
dc.source.bibliographicCitationRipamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol [Internet]. 2012 Oct [cited 2015 Apr 30];23 Suppl 7(Supplement 7):vii139–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22997447
dc.source.bibliographicCitationEd M, Midbari a, Eisenberg E, Mcnicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain ( Review ) Opioids for neuropathic pain. 2013;(9):9–11.
dc.source.bibliographicCitationManuel Gonzalez Barón. ANALES REAL ACADEMIA NACIONAL DE MEDICINA. 2000.
dc.source.bibliographicCitationVacia L silla. Proyecto de Galán (Lo que dijo santos y todos los estudios y linea histórica que ayudan a argumentar a Galan) [Internet]. Available from: http://lasillavacia.com/sites/default/files/files/SEGUNDO PROYECTO AL 02 DE 2009 VF(1).
dc.source.bibliographicCitationMPS Ministerio de la Protección social. Decreto Número 2467 de 2015.
dc.source.bibliographicCitationEl ABC del decreto. Ministerio de salud (el abc del decreto) [Internet]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/abc-canabis.
dc.source.bibliographicCitationAlejandro Gaviria Uribe. La marihuana con uso terapéutico en el contexto colombiano. Ministerio de Salud y Protección Social. 2014
dc.source.bibliographicCitationRevista Semana. Noticias sobre la ley [Internet]. Available from: http://www.semana.com/nacion/articulo/marihuana-medicinal-es-aprobada-en-el-congreso/475155
dc.source.bibliographicCitationAndre CM, Hausman J-F, Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front Plant Sci [Internet]. 2016;7(February):19. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4740396&tool=pmcentrez&rendertype=abstract
dc.source.bibliographicCitationGuerriero G, Hausman JF, Strauss J, Ertan H, Siddiqui KS. Lignocellulosic biomass: Biosynthesis, degradation, and industrial utilization. Eng Life Sci. 2016;16(1):1–16.
dc.source.bibliographicCitationBaker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–8
dc.source.bibliographicCitationKiran Vemuri V, Makriyannis A. Medicinal Chemistry of Cannabinoids. Clin Pharmacol Ther. 2015;97(6):553–8
dc.source.bibliographicCitationNiesink RJM, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front psychiatry [Internet]. 2013;4(October):130
dc.source.bibliographicCitationHarris CR, Brown A. Synthetic cannabinoid intoxication: A case series and review. J Emerg Med [Internet]. Elsevier Ltd; 2013;44(2):360–6.
dc.source.bibliographicCitationBreivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry. 2009;21(2):113–21
dc.source.bibliographicCitationDevane W a, Hanus L, Breuer A, Pertwee RG, Stevenson L a, Griffin G, et al. Constituent Receptor. Science (80- ). 1992;258(10):1946–9.
dc.source.bibliographicCitationMatsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature [Internet]. 1990 Aug 9 [cited 2015 Jan 27];346(6284):561–4.
dc.source.bibliographicCitationMunro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature [Internet]. 1993 Sep 2 [cited 2014 Dec 14];365(6441):61–5.
dc.source.bibliographicCitationKreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 2001;29(3):717–27.
dc.source.bibliographicCitationWilson RI, Nicoll R a. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588–92.
dc.source.bibliographicCitationElphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci [Internet]. 2001;356(1407):381–408.
dc.source.bibliographicCitationGuindon J, Hohmann a G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319–34.
dc.source.bibliographicCitationHerkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A [Internet]. 1990;87(5):1932–6.
dc.source.bibliographicCitationSzabo B, Dörner L, Pfreundtner C, Nörenberg W, Starke K. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience [Internet]. 1998 Jul [cited 2016 May 26];85(2):395–403.
dc.source.bibliographicCitationLévénés C, Daniel H, Soubrié P, Crépel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J Physiol [Internet]. 1998 Aug 1 [cited 2016 May 26];510 ( Pt 3:867–79.
dc.source.bibliographicCitationJennings EA, Vaughan CW, Christie MJ. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol. 2001;534(3):805–12.
dc.source.bibliographicCitationGifford AN, Ashby CR. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther [Internet]. 1996 Jun [cited 2016 May 26];277(3):1431–6.
dc.source.bibliographicCitationIshac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol [Internet]. 1996 Aug [cited 2016 May 26];118(8):2023–8.
dc.source.bibliographicCitationCadogan AK, Alexander SP, Boyd EA, Kendall DA. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J Neurochem [Internet]. 1997 Sep [cited 2016 May 26];69(3):1131–7.
dc.source.bibliographicCitationNakazi M, Bauer U, Nickel T, Kathmann M, Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(1):19–24.
dc.source.bibliographicCitationBeltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci [Internet]. 2006 Mar [cited 2016 May 26];23(6):1530–8.
dc.source.bibliographicCitationTs-- S, Shaaban KA, Singh S, Elshahawi SI, Wang X, Larissa V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. 2014;67(3):223–30.
dc.source.bibliographicCitationKano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89(1):309–80
dc.source.bibliographicCitationOhno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci [Internet]. 2002 May 15 [cited 2016 May 26];22(10):3864–72.
dc.source.bibliographicCitationKano M, Ohno-shosaku T, Hashimotodani Y. Endocannabinoid-Mediated Control of Synaptic Transmission. 2009;309–80.
dc.source.bibliographicCitationRyberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol [Internet]. 2007 Dec [cited 2016 Apr 6];152(7):1092–101
dc.source.bibliographicCitationStarowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther [Internet]. 2007 Apr [cited 2016 Apr 3];114(1):13–33.
dc.source.bibliographicCitationJones RCW, Lawson E, Backonja M. Managing Neuropathic Pain. Med Clin North Am. 2016;100(1):151–67.
dc.source.bibliographicCitationZogopoulos P, Vasileiou I, Patsouris E, Theocharis SE. The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol. 2013;27(1):64–80.
dc.source.bibliographicCitationCravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61(1):149–60.
dc.source.bibliographicCitationRomero TRL, Resende LC, Guzzo LS, Duarte IDG. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth Analg. 2013;116(2):463–72.
dc.source.bibliographicCitationRichardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain [Internet]. 1998 Mar [cited 2016 May 26];75(1):111–9.
dc.source.bibliographicCitationIbrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A [Internet]. 2005;102(8):3093–8.
dc.source.bibliographicCitationSchmidt BL, Schmidt BL. The Neurobiology of Cancer Pain\r. 2014;(March).
dc.source.bibliographicCitationIASP Taxonomy 2012 update [Internet]. IASP Taxonomy. 2012. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698
dc.source.bibliographicCitationBoard E. Diagnosis and Classifi cation of Neuropathic Pain Epidemiology and Impact of Neuropathic Pain. Pain Med. 2010;XVIII(7):1–6
dc.source.bibliographicCitationDubin AE, Patapoutian A. Nociceptors: The sensors of the pain pathway. Journal of Clinical Investigation. 2010. p. 3760–72
dc.source.bibliographicCitationWoolf CJ, Ma Q. Nociceptors-Noxious Stimulus Detectors. Neuron. 2007;55(3):353–64.
dc.source.bibliographicCitationRathmell JP, Hill B. Wall and Melzack’s Textbook of Pain, 5th E-dition. Anesth Analg [Internet]. 2006;102(6). Available from: http://journals.lww.com/anesthesia-analgesia/Fulltext/2006/06000/Wall_and_Melzack_s_Textbook_of_Pain,_5th_E_dition_.78.aspx
dc.source.bibliographicCitationTracey I, Mantyh PW. The Cerebral Signature for Pain Perception and Its Modulation. Neuron. 2007;55(3):377–91.
dc.source.bibliographicCitationRomera E, Perena MJ, Rodrigo MFPMD. Neurofisiología del dolor. Rev Soc Esp Dolor. 2000;7(II):11–7.
dc.source.bibliographicCitationOssipov MH, Dussor GO, Porreca F. Review series Central modulation of pain. J Clin Invest. 2010;120(11):3779–87.
dc.source.bibliographicCitationVadalouca A, Raptis E, Moka E, Zis P, Sykioti P, Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract [Internet]. 2012;12:219–51.
dc.source.bibliographicCitationMols F, Beijers T, Vreugdenhil G, Van De Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer. 2014;22(8):2261–9.
dc.source.bibliographicCitationHershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67
dc.source.bibliographicCitationWolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–15.
dc.source.bibliographicCitationPark SB, Goldstein D, Krishnan A V, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin [Internet]. 2013;63(6):419–37.
dc.source.bibliographicCitationArticle R. Chemotherapy-induced peripheral neuropathy : review for clinical practice *. 2015;16(3):215–20
dc.source.bibliographicCitationCaraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage. 2002;23(3):239–55.
dc.source.bibliographicCitationDownie WW, Leatham P a, Rhind VM, Wright V, Branco J a, Anderson J a. Studies with pain rating scales. Ann Rheum Dis. 1978;37(4):378–81.
dc.source.bibliographicCitationPlancarte Sánchez R, Guajardo Rosas J, Guillén Nuñez R. Manejo integral del dolor. Cancerología. 2006;1:273–81.
dc.source.bibliographicCitationWang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ [Internet]. 2008;178(13):1669–78
dc.source.bibliographicCitationWhiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez A V, et al. Cannabinoids for Medical Use. Jama [Internet]. 2015;313(24):2456.
dc.source.bibliographicCitationPöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs [Internet]. 2008 Jan [cited 2016 May 26];22(4):291–324.
dc.source.bibliographicCitationAbrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007;68(7):515–21.
dc.source.bibliographicCitationJohnson JR, Chb MB, Burnell-nugent M, Bchir MB, Lossignol D, Chb MB, et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain - pdf. 2010;39(2):167–79.
dc.source.bibliographicCitationMerskey H, Bogduk N. Classification of Chronic Pain. IASP Pain Terminology. 1994. 240 p.
dc.source.bibliographicCitationM. FJYJJLLWJP. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical rating scale. Pain. 2001;94(2):149–58.
dc.source.bibliographicCitationministerio de salud y proteccion social I. ABC Seguridad 2014. ABC-Seguridad en el uso Medicam [Internet]. 2016;10–30.
dc.source.bibliographicCitationWilliam; Sackett, David L; Straus SER. Evidence-based medicine: How to practice and teach EBM. 2000. 1-27 p
dc.source.bibliographicCitationWelch V, Petticrew M, Tugwell P, Moher D, Neill JO, Waters E et al. Extensión PRISMA-Equidad 2012 : guías para la escritura y la publicación de revisiones sistemáticas enfocadas en la equidad en salud. Rev Panam Salud Pública. 2013;34(4):60–8.
dc.source.bibliographicCitationMPS Ministerio de la Protección social. Resolucion 8430/1993 Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación á. Bogotá. 1993.
dc.source.bibliographicCitationAbrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther [Internet]. 2011;90(6):844–51.
dc.source.bibliographicCitationCichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther. 1999;289(2):859–67.
dc.source.bibliographicCitationWare MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Cmaj. 2010;182(14).
dc.source.bibliographicCitationRamaekers JG, van Wel JH, Spronk DB, Toennes SW, Kuypers KPC, Theunissen EL, et al. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Sci Rep [Internet]. Nature Publishing Group; 2016;6(May):26843.
dc.source.bibliographicCitationLynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. Elsevier Inc; 2014;47(1):166–73
dc.source.bibliographicCitationFinnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain [Internet]. International Association for the Study of Pain; 2010;150(3):573–81. Available from: http://dx.doi.org/10.1016/j.pain.2010.06.019
dc.source.bibliographicCitationPortenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.
dc.source.bibliographicCitationClark J, Cunningham M, McMillan S, Vena C, Parker K. Sleep-wake disturbances in people with cancer part II: evaluating the evidence for clinical decision making. Oncol Nurs Forum. 2004;31(4):747–71.
dc.source.bibliographicCitationJohnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–18.
dc.source.bibliographicCitationWilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9(6):506–21.
dc.source.bibliographicCitationCancer, Neuropathic cancer pain, cannabinoids, Neuropathic pain, oncologic pain
dc.source.bibliographicCitationAlexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2009;285(1):6–12.
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectCáncerspa
dc.subjectDolor Neuropático por cáncerspa
dc.subjectCannabinoidesspa
dc.subject.ddcFisiología humana
dc.subject.decsOncología Médicaspa
dc.subject.decsCannabinoidesspa
dc.subject.decsNeuralgiaspa
dc.subject.decsDolor Crónicospa
dc.subject.decsCannabisspa
dc.subject.keywordCancereng
dc.subject.keywordNeuropathic paineng
dc.subject.keywordOncologic paineng
dc.subject.keywordCannabinoidseng
dc.titleEvidencia sobre la eficacia de cannabinoides en el dolor neuropático oncológicospa
dc.typemasterThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 2 de 2
Miniatura
Nombre:
BarbosaVillada-Maria-2016.pdf
Tamaño:
734.04 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Miniatura
Nombre:
BarbosaVillada-Maria-2016.pdf
Tamaño:
734.04 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Toxicología Clínica